Mmrc partners with celgene corporation on phase i/ii trial of pomalidomide in relapsed and refractory multiple myeloma patients
August 29th, 2008 by 
admin The Multiple Myeloma Research Consortium (MMRC) declared the institution of a clinical effort with the test immunomodulatory businessperson pomalidomide (CC-4047) in patients who hit conventional at small digit preceding therapies including treatments with REVLIMID® (lenalidomide) and VELCADE® (bortezomib) for Injection. (Source: Lymphoma / Leukemia News From Medical News Today)
Tags: ATM, Initiation, leukemia, Lim, Research Co
Posted in Cancer | 